+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Parathyroid Hormone Interferes with Extrarenal Disposition of Potassium in Chronic Renal Failure

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Available data suggest that the permeability of cellular membranes to potassium is affected by cytosolic calcium. Parathyroid hormone (PTH) has a calcium ionophoric property; it enhances calcium entry into many cells and it increases calcium content in a variety of tissues. Therefore, it is possible that clinical states with excess PTH may affect potassium homeostasis. The present study examined the effect of secondary hyperparathyroidism of chronic renal failure (CFR) on extrarenal potassium disposition of intravenous KC1 load in rats with CRF. Experiments were performed after 21–26 days of CRF produced by 7/8 nephrectomy in rats with intact parathyroid glands (CRF control), in normocalcemic parathyroidectomized CRF animals (CFR-PTX) and in adrenalectomized CRF rats (CRF-ADX) maintained with DOC A. The effects of treatment with calcium channel blocker, verapamil, and of PTH administration were also examined. The baseline plasma concentrations of potassium in CRF-PTX rats and in CRF control animals treated with verapamil were significantly (p < 0.01) lower than those with CRF control and CRF-ADX rats. At the end of 90 min of KC1 infusion, the plasma concentrations of potassium as well as the changes from baseline were significantly (p < 0.01) higher in CRF animals with secondary hyperparathyroidism (CRF control and CRF-ADX) and in those treated with PTH (CRF control with PTH and CRF-PTX with PTH) than in those without secondary hyperparathyroidism CRF-PTX and in those with secondary hyperparathyroidism but treated with verapamil (CRF control with verapamil and CRF-ADX with verapamil). The percents of potassium load translocated from extracellular space to cells in CRF-PTX rats (80 ± 4.4%), in CRF control rats with verapamil (79 ± 2.3%) and in CRF-ADX rats with verapamil (76 ± 1.4%) were significantly (p < O.Ol) higher than those in CRF control animals (67 ± 2.8%), in CRF control rats treated with PTH (59 ± 0.9%), in CRF-PTX animals treated with PTH (60 ± 2.0%) and in CRF-ADX rats (65 ± 1.4%). The data show that the state of secondary hyperparathyroidism of CRF interferes with extrarenal disposal of potassium. This derangement could be prevented by parathyroidectomy or by treatment with verapamil. Our results are consistent with the notion that this effect of excess PTH is mediated by the calcium ionophoric property of the hormone.

          Related collections

          Author and article information

          S. Karger AG
          10 December 2008
          : 52
          : 3
          : 262-267
          Division of Nephrology and the Department of Medicine, The University of Southern California School of Medicine, Los Angeles, Calif., USA
          185654 Nephron 1989;52:262–267
          © 1989 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Original Paper


          Comment on this article